Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9449822 | 0.81 | ALDH1A1 (0.37) | MAPTALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL9450207 | 0.81 | RECQL (0.35) | TSHRALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL4465079 | 0.73 | — | — | |
| SCHEMBL429672 | 0.69 | TSHR (0.42) | KMT2ATSHRMAPTHTTL3MBTL1 | |
| SCHEMBL8919629 | 0.69 | L3MBTL1 (0.38) | KMT2ACYP1A2TSHRMAPTHTT | |
| SCHEMBL97108 | 0.68 | HSD17B10 (0.48) | KMT2ACYP1A2TSHRMAPTHPGD | |
| SCHEMBL9450315 | 0.68 | — | — | |
| SCHEMBL5158336 | 0.68 | SMN1; SMN2 (0.34) | KMT2ATSHRMAPTHPGDHTT | |
| SCHEMBL27971476 | 0.66 | PIK3CA (0.52) | CYP1A2HPGDALDH1A1TDP1PIK3CA | |
| SCHEMBL6544881 | 0.65 | KMT2A (0.35) | KMT2AALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036291-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | claimed |
| CN-118005611-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20210379211-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2021-12-09 | — | — | US | claimed |
| EP-3186241-B1 | PROBES FOR IMAGING HUNTINGTON PROTEIN | CHDI FOUNDATION INC (US) | 2020-10-07 | — | — | EP | claimed |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-10-12 | — | — | US | claimed |
| US-20170281804-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | claimed |
| EP-3190888-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| EP-3186241-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-05 | — | — | EP | claimed |
| WO-2016033436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | claimed |
| WO-2016033460-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | claimed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-12036291-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118005611-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-107074817-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-1996011690-A1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | INSTITUT DE RECHERCHE JOUVEINAL (FR) | 1996-04-25 | — | — | WO | disclosed |
| US-5232978-A | 1-(2-arylethyl)-pyrrolidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-08-03 | — | — | US | disclosed |
| EP-0483580-A2 | 1-(2-Arylethyl)-pyrrolidine | MERCK PATENT GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379211-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | KMT2A 3799/4885CYP1A2 4836/4885TSHR 3168/4885 |
| US-20170281804-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | KMT2A 3799/4885CYP1A2 4836/4885TSHR 3168/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | KMT2A 1296/4885CYP1A2 4746/4885TSHR 3588/4885 |
| US-12036291-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | KMT2A 3799/4885CYP1A2 4836/4885TSHR 3168/4885 |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | KMT2A 3894/4885CYP1A2 4815/4885TSHR 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.